Breakfast with the Investigators: Management of Melanoma

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Dr Michael A Postow, Prof Caroline Robert and Dr Jeffrey Weber.

1.5 AMA PRA Category 1 Credits^™

To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CME credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Related links:

Home
CME evaluation
CME information and faculty disclosures
Select publications
PowerPoint slides

Introduction
Program Overview: Dr Love
Evolving Treatment Approaches for Patients with Localized or Locally Advanced Disease
Case (Dr Postow): A 32-year-old woman with BRAF-mutant melanoma of the left arm who received adjuvant dabrafenib/trametinib
Case (Dr Weber): A 48-year-old man who presented with Stage IIIC BRAF wild-type melanoma and received adjuvant nivolumab
Case (Prof Robert): A 45-year-old man with BRAF-mutant nodular melanoma who entered a clinical trial of adjuvant pembrolizumab versus placebo
Integration of BRAF/MEK Inhibitors into the Management of BRAF-Mutated Disease
Case (Dr Postow): A 61-year-old woman with BRAF-mutant metastatic melanoma who discontinued treatment with dabrafenib/trametinib because of recurring fevers
Case (Dr Weber): A 52-year-old woman with BRAF-mutant metastatic melanoma who experienced a complete response on a trial of encorafenib/binimetinib
Immune Checkpoint Inhibitors in Metastatic Melanoma; Management of Autoimmune Toxicities
Case (Dr Postow): A 55-year-old man with BRAF wild-type metastatic melanoma who developed automimmune hypophysitis while receiving nivolumab/ipilimumab